{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a recent study (1) focused on renal cell carcinoma (RCC), CCNT2‐AS1 was identified as one of nine key long non‐coding RNAs (lncRNAs) that collectively form a prognostic signature for patients with advanced disease (stage IV and histological grade G4). The study employed data from the SEER database and The Cancer Genome Atlas to correlate clinical characteristics and molecular profiles with patient outcomes. Notably, CCNT2‐AS1, along with the other lncRNAs in the signature, is implicated in critical cellular processes—including cell division, cell cycle regulation, DNA damage response, and modulation of cytokine levels—which may influence tumor progression and overall survival in RCC patients.\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n (1)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Ning Li, Haiying Zhang, Keyao Hu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A novel long non-coding RNA-based prognostic signature for renal cell carcinoma patients with stage IV and histological grade G4."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Bioengineered (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1080/21655979.2021.1971022"}], "href": "https://doi.org/10.1080/21655979.2021.1971022"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34499010"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34499010"}]}]}]}